Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21237810 | 0.85 | CYP11B1 (0.63) | CYP11B1CYP11B2 | |
| SCHEMBL28643620 | 0.80 | CYP11B1 (0.62) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL6882198 | 0.79 | CYP11B1 (0.41) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL21910589 | 0.75 | CYP11B1 (0.39) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL1662324 | 0.75 | KDM1A (0.50) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL13578617 | 0.75 | CYP11B1 (0.39) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL92259 | 0.72 | GABRP (0.38) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL18822948 | 0.71 | CYP11B1 (0.48) | CYP11B1CYP11B2 | |
| SCHEMBL6867644 | 0.71 | MEN1 (0.43) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL20093956 | 0.70 | CYP11B2 (0.47) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. | 2012-05-24 | — | — | US | disclosed |
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2009154780-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154780-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129828-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | S1PR1, S1PR5, S1PR2 | CYP11B1 503/4885CYP11B2 678/4885MEN1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.